Compare Quest Diagnostics Inc (DGX) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Zillow Group Inc Class C — how do they compare? Quest Diagnostics Inc trades at $237.64 (market cap $26.21B), while Zillow Group Inc Class C trades at $33.21 (market cap $7.68B). The key difference: Quest Diagnostics Inc is far larger — about 3.4× Zillow Group Inc Class C's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Zillow Group Inc Class C pays none. Which is the better fit depends on your goals.
| DGX | Z | |
|---|---|---|
Market Cap | $26.21B | $7.68B |
Sector | Health | Media |
52-Week High | $238.50 | $90.35 |
52-Week Low | $173.49 | $29.41 |
Enterprise Value | $31.97B | $7.56B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Zillow Group (Z) trades at $33.10, down 1.93% on the day, with a bearish technical signal and mixed earnings history. Revenue growth is solid, rising to $2.58B in 2025, but profitability remains thin with a net margin of 1.96%. The stock faces headwinds from a securities class action lawsuit and a challenging real estate market, though analyst consensus points to significant upside with a $52 price target.
The outlook is cautious due to legal risks and weak near-term profitability, but long-term monetization potential and analyst optimism suggest opportunity if execution improves. Key risks include litigation outcomes and market volatility, while institutional sentiment leans neutral with a 50% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
